367 related articles for article (PubMed ID: 30769200)
1. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
2. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
[TBL] [Abstract][Full Text] [Related]
3. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
[TBL] [Abstract][Full Text] [Related]
5. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
6. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT
Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152
[TBL] [Abstract][Full Text] [Related]
7. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
[TBL] [Abstract][Full Text] [Related]
8. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
[TBL] [Abstract][Full Text] [Related]
10. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Feng M; Wang D; Grobler JA; Hazuda DJ; Miller MD; Lai MT
Antimicrob Agents Chemother; 2015 Jan; 59(1):590-8. PubMed ID: 25385110
[TBL] [Abstract][Full Text] [Related]
11. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
12. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY;
Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446
[TBL] [Abstract][Full Text] [Related]
13. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
14. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
[TBL] [Abstract][Full Text] [Related]
15. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
[TBL] [Abstract][Full Text] [Related]
16. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
[TBL] [Abstract][Full Text] [Related]
17. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
18. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
[TBL] [Abstract][Full Text] [Related]
19. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
[TBL] [Abstract][Full Text] [Related]
20. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
